Cargando…
Biological patent thickets and delayed access to biosimilars, an American problem
Our study seeks to determine whether patent thickets covering biologic drugs are responsible for delayed biosimilar market entry. We compare patent assertions against the same biosimilar drugs across three countries. On average nine to twelve times more patents were asserted against biosimilars in t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439849/ https://www.ncbi.nlm.nih.gov/pubmed/36072417 http://dx.doi.org/10.1093/jlb/lsac022 |